GlassScriptPhysician profile
Stephanie Johnson
NPI 1841844685
$9,112.47
in general payments reported to CMS, 2019-2025
29 companies · $2,069 in 2025
The $2,069 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $893 · 2022: $1,681 · 2023: $1,744 · 2024: $2,725 · 2025: $2,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,708 · Travel and Lodging: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,708.39 |
| Travel and Lodging | $829.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,465.59 | 2022-2025 | Xifaxan |
| Gilead Sciences, INC. | $1,354.77 | 2022-2025 | Vemlidy, Livdelzi |
| Amgen INC. | $1,135.68 | 2021-2024 | |
| Novo Nordisk INC | $834.71 | 2021-2024 | Wegovy |
| Siemens Medical Solutions USA, INC. | $805.70 | 2022-2024 | Naeotom Alpha, Magnetom Sola, Diagnostic Ultrasound System |
| Madrigal Pharmaceuticals | $748.96 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $535.86 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $523.14 | 2022-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $344.94 | 2023-2025 | Iqirvo, Bylvay |
| Orphalan INC | $335.92 | 2024-2025 | Cuvrior |
| Albireo Pharma, INC. | $149.75 | 2023 | Bylvay |
| Lilly USA, LLC | $124.52 | 2021-2022 | |
| Intra-Sana Laboratories | $100.00 | 2022 | |
| Eisai INC. | $89.55 | 2021 | |
| Nalu Medical, INC. | $85.40 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $79.86 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $73.43 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.56 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.19 | 2022 | |
| Ardelyx, INC. | $34.77 | 2023 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $27.99 | 2025 | Livtencity |
| Organon LLC | $27.05 | 2022 | |
| Sanofi-Aventis U.S. LLC | $27.02 | 2021 | |
| Fujifilm Healthcare Americas Corporation | $22.65 | 2025 | |
| Glaxosmithkline, LLC. | $21.05 | 2021 | |
| Exact Sciences Corporation | $20.59 | 2024 | |
| Amarin Pharma, INC. | $17.68 | 2022 | |
| Medicure Pharma INC. | $16.64 | 2022 | |
| Genentech USA, INC. | $6.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.